% Expired Patents = 25.0

EPO Patents = 2

Forward Citations = 28

Loading Chart...

4 inventors (with patents filed for the assignee):

Charles Larry Bisgaier (3 out of 18 patents)

Daniela Carmen Oniciu (2 out of 13 patents)

Otto Joseph Geoffroy (1 out of 3 patents)

4. Carmen Daniela Oniciu (1 out of 31 patents)

4 patents: Sort by Forward Citations

1. 10449154 - Treatment of NASH with Gemcabene (2019-10-22),

2. 10227285 - Processes and intermediates for preparing alpha,omega-dicarboxylic acid-terminated dialkane ethers (2019-03-12),

3. 10028926 - Methods of reducing risk of cardiovascular disease (2018-07-24),

4. 9849104 - Treatment of NASH with gemcabene (2017-12-26),

Gemphire Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of cardiometabolic disorders. The company's lead product candidate, gemcabene, is being developed to address high cholesterol and fatty liver disease. Gemphire's mission is to improve the lives of patients by advancing innovative treatments that target unmet medical needs in the cardiovascular and metabolic disease space.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

4 Patents

#33 in Livonia, MI

#2,021 in Michigan

#60,597 in US

Livonia, MI, United States of America

Gemphire Therapeutics Inc.

Forward Citations = 28

4 inventors:

Charles Larry Bisgaier (3 out of 18 patents)

Daniela Carmen Oniciu (2 out of 13 patents)

Otto Joseph Geoffroy (1 out of 3 patents)

4. Carmen Daniela Oniciu (1 out of 31 patents)

Please report any incorrect information to [email protected]

2 patents (EPO):

Please report any incorrect information to [email protected]